Meeting
2020 Genitourinary Cancers Symposium
Association of high plasma glutamine levels with outcome in metastatic castration-resistant prostate (mCRPC) patients treated with taxanes.
Authors
Veronica Pereira Diaz
Hospital Sagrat Cor, Barcelona, Spain
Veronica Pereira Diaz , Mercedes Marin , Natalia Jiménez , Oscar Reig , Iván Victoria , Francis Esposito , Aleix Prat , Begona Mellado
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 164)
Abstract #
164
Poster Bd #
G22
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri
Poster
2018 Genitourinary Cancers Symposium
Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Avina Rami